ZD6474

From WikiMD.org
Jump to navigation Jump to search

ZD6474

ZD6474 (pronounced Zee-Dee-Six-Four-Seven-Four), also known as Vandetanib (pronounced Van-de-ta-nib), is a small molecule pharmaceutical drug designed to inhibit the receptor tyrosine kinases of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and RET proto-oncogene (RET). It is primarily used in the treatment of certain types of thyroid cancer and non-small cell lung cancer.

Etymology

The name "ZD6474" is a code name given by the drug's developer, AstraZeneca. The "ZD" prefix is commonly used in AstraZeneca's investigational compounds, while the numbers "6474" are arbitrary and do not hold any specific meaning. The generic name "Vandetanib" is derived from the drug's mechanism of action, with "van" referring to VEGFR and "de" referring to EGFR, the two main targets of the drug.

Mechanism of Action

ZD6474 works by inhibiting the activity of certain protein kinases, specifically EGFR, VEGFR, and RET. These kinases are involved in the growth and spread of cancer cells. By inhibiting these kinases, ZD6474 can slow down or stop the growth of cancer cells.

Related Terms

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski